Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cannabix Technologies Inc. (C:BLO)

Business Focus: Advanced Medical Equipment & Technology

Log in or join to add this stock to your watch list.
Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEDAR
Company Contact
Address: 501-3292 Production Way
BURNABY BC V5A 4R4
Tel: N/A
Website: www.cannabixtechnologies.com
IR: See website
Key People
Kulwant Sing Malhi
President, Director
Ravinder S. Mlait
Chief Executive Officer, Director
Bryan E. Loree
Chief Financial Officer, Secretary, Director
Business Overview
Cannabix Technologies Inc is a Canada-based company, which is engaged in Marijuana Breathalyzer development for law enforcement and the workplace. The Company is developing breath testing technologies in the pursuit of bringing durable, portable hand-held tools to the market to enhance detection of marijuana impaired driving offences on roads. The Company offers Beta 2.0 Cannabix Marijuana Breathalyzer. The Company is developing drug-testing devices that detect the psychoactive component (THC) of marijuana that causes intoxication-using breath samples. The Company also develops breath-testing devices for detection of use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The Company's breath-testing devices are also useful for other practical applications, such as testing employees in the workplace where intoxication by THC can be hazardous.
Financial Overview
For the nine months ended 31 January 2019, Cannabix Technologies Inc revenues was not reported. Net loss increased from C$991K to C$3.1M. Higher net loss reflects Share-based compensation increase from C$0K to C$1.9M (expense), Research and development increase of 22% to C$753K (expense), Advertising and promotion increase from C$7K to C$47K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -C$0.01 to -C$0.03.
Reporting Currency: Canadian Dollars
Enterprise value: $56.44M as of Jan 31, 2019
Annual revenue (TTM): $0.00M as of Jan 31, 2019
EBITDA (TTM): -$3.56M as of Jan 31, 2019
Net annual income (TTM): -$3.55M as of Jan 31, 2019
Free cash flow (TTM): -$1.47M as of Jan 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 102,992,374 as of Jan 31, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization